French biotech Poxel is trying to stabilise its business after judicial reorganisation, with its court-approved recovery plan now moving into the execution phase. The Lyon-based company, which has spent the past year under financial pressure, received approval from the Commercial Court of Lyon last week to restructure its debt and continue operations.
Newly formed French biotech Kahimmune Therapeutics has signed an exclusive licensing agreement with Gustave Roussy and SATT Paris-Saclay, securing rights to a technology platform designed to identify tumor antigens derived from the “dark” or non-coding genome. The spin-off, created in late 2025, plans to use the licensed technology to develop shared mRNA cancer vaccines, with an initial program targeting colorectal and pancreatic cancer.
French Afyren secures €23m to accelerate biorefinery expansion as first plant enters full industrial ramp-up. Most of the money comes from US company Kemin Industries.
French CARBIOS SA signs strategic agreement with Indorama Ventures and Michelin amid broader company transition and sees itself back on track. Before opening of its production plant (delayed to later in 2026), the company has shown some success in concluding production agreements with several larger industry corporates.
French ERBC and Menarini Biotech from Italy forge a new strategic alliance to accelerate biopharmaceutical development.
Not the German InFamily Foods subsidiary The Cultivated B, but Gourmey SAS, founded in Paris in 2019 by Antoine Davydoff, Nicolas Morin-Forest and Victor Sayous, has submitted the first EU authorisation application for a cell-based meat product, a duck liver pâté (Foie gras), to the European Food Safety Authority (EFSA).
The French Republicans have tabled a bill in the National Assembly aimed at banning the commercialisation of cell-based meat in France.
Valneva has appointed Dipal Patel as new Chief Commercial Officer and Management Board member.
French MaaT Pharma has appointed Nathalie Corvaïa as Chief Scientific Officer and will strengthens its R&D Activities in Immuno-Oncology.
Finance Expert Pascal Bricout strengthens French Carbios as Chief of Strategy; Financial Officer and a member of the Executive Committee.
Afyren Group
Carbios SA
Menarini Group
Romain Buisson